Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine were evaluated in HIV-positive Spanish MSM. The prevalence of High Squamous Intraepithelial Lesions (HSIL) and genotypes of high-risk human papillomavirus (HR-HPV) were also determined, as well as risk factors associated with the presence of HR-HPV in anal mucosa.This is a randomised, double blind, placebo-controlled trial of the quadrivalent HPV (qHPV) vaccine. The study enrolled from May 2012 to May 2014. Vaccine and placebo were administered at 0, 2 and 6 months (V1, V2, V3 clinical visits). Vaccine antibody titres were evaluated at 7 months. Cytology (Thin Prep® Pap Test), HPV PCR genotyping (Linear Array HPV Genotyping Test), and high-resolution anoscopy (Zeiss 150 fc© colposcope) were performed at V1.Patients (n = 162; mean age 37.9 years) were screened for inclusion; 14.2

作者：Carmen, Hidalgo-Tenorio；Jessica, Ramírez-Taboada；Concepción, Gil-Anguita；Javier, Esquivias；Mohamed, Omar-Mohamed-Balgahata；Antonio, SamPedro；Miguel, Lopez-Ruz；Juan, Pasquau

来源：AIDS research and therapy 2017 年 14卷